FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991451517> ?p ?o ?g. }

• W1991451517 endingPage "e55" @default.
• W1991451517 startingPage "e49" @default.
• W1991451517 abstract "Background: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0–1–12 months) compared with the standard dosing schedule (0–1–6 months). Methods: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, 1, and 12 (n = 403). HPV-16 and -18 antibodies were measured by enzyme-linked immunosorbent assay at months 0, 2, and 7 or 13 (depending on group); noninferiority evaluation was performed sequentially for seroconversion rates and geometric mean antibody titers. Primary analysis of immunogenicity was based on the according-to-protocol cohort. Vaccine safety and reactogenicity were assessed on the total vaccinated cohort. Results: Predefined noninferiority criteria were met 1 month after the third vaccine dose when the HPV-16/18 vaccine was administered according to the 0–1–12 month schedule compared with the 0–1–6 month schedule in terms of seroconversion rates for HPV-16 (100% and 100%) and HPV-18 (99.7% and 100%) and geometric mean antibody titers for HPV-16 (11884.7 and 10311.9 ELISA units/mL) and HPV-18 (4501.3 and 3963.6 ELISA units/mL), respectively. The HPV-16/18 vaccine had a clinically acceptable safety profile when administered according to either schedule. Conclusions: The third dose of the HPV-16/18 vaccine can be administered any time between 6 and 12 months after the first dose, with adequate immunogenicity and a clinically acceptable safety profile." @default.
• W1991451517 created "2016-06-24" @default.
• W1991451517 creator A5003684141 @default.
• W1991451517 creator A5004634899 @default.
• W1991451517 creator A5011118237 @default.
• W1991451517 creator A5024245378 @default.
• W1991451517 creator A5033799575 @default.
• W1991451517 creator A5045375634 @default.
• W1991451517 creator A5065131913 @default.
• W1991451517 creator A5071230943 @default.
• W1991451517 creator A5071913631 @default.
• W1991451517 creator A5074276659 @default.
• W1991451517 date "2011-03-01" @default.
• W1991451517 modified "2023-10-18" @default.
• W1991451517 title "Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years" @default.
• W1991451517 cites W1965782309 @default.
• W1991451517 cites W2014623932 @default.
• W1991451517 cites W2047580791 @default.
• W1991451517 cites W2050180799 @default.
• W1991451517 cites W2081619150 @default.
• W1991451517 cites W2083182154 @default.
• W1991451517 cites W2092013767 @default.
• W1991451517 cites W2095794160 @default.
• W1991451517 cites W2098491904 @default.
• W1991451517 cites W2101196984 @default.
• W1991451517 cites W2109245506 @default.
• W1991451517 cites W2113802001 @default.
• W1991451517 cites W2114813165 @default.
• W1991451517 cites W2123658370 @default.
• W1991451517 cites W2136236728 @default.
• W1991451517 cites W2139349670 @default.
• W1991451517 cites W2150436558 @default.
• W1991451517 cites W2159831861 @default.
• W1991451517 cites W2171755920 @default.
• W1991451517 doi "https://doi.org/10.1097/inf.0b013e318206c26e" @default.
• W1991451517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21273939" @default.
• W1991451517 hasPublicationYear "2011" @default.
• W1991451517 type Work @default.
• W1991451517 sameAs 1991451517 @default.
• W1991451517 citedByCount "37" @default.
• W1991451517 countsByYear W19914515172012 @default.
• W1991451517 countsByYear W19914515172013 @default.
• W1991451517 countsByYear W19914515172014 @default.
• W1991451517 countsByYear W19914515172015 @default.
• W1991451517 countsByYear W19914515172016 @default.
• W1991451517 countsByYear W19914515172017 @default.
• W1991451517 countsByYear W19914515172018 @default.
• W1991451517 countsByYear W19914515172019 @default.
• W1991451517 countsByYear W19914515172020 @default.
• W1991451517 countsByYear W19914515172023 @default.
• W1991451517 crossrefType "journal-article" @default.
• W1991451517 hasAuthorship W1991451517A5003684141 @default.
• W1991451517 hasAuthorship W1991451517A5004634899 @default.
• W1991451517 hasAuthorship W1991451517A5011118237 @default.
• W1991451517 hasAuthorship W1991451517A5024245378 @default.
• W1991451517 hasAuthorship W1991451517A5033799575 @default.
• W1991451517 hasAuthorship W1991451517A5045375634 @default.
• W1991451517 hasAuthorship W1991451517A5065131913 @default.
• W1991451517 hasAuthorship W1991451517A5071230943 @default.
• W1991451517 hasAuthorship W1991451517A5071913631 @default.
• W1991451517 hasAuthorship W1991451517A5074276659 @default.
• W1991451517 hasConcept C121608353 @default.
• W1991451517 hasConcept C126322002 @default.
• W1991451517 hasConcept C159654299 @default.
• W1991451517 hasConcept C203014093 @default.
• W1991451517 hasConcept C2777288759 @default.
• W1991451517 hasConcept C2777451964 @default.
• W1991451517 hasConcept C2777704310 @default.
• W1991451517 hasConcept C2778220009 @default.
• W1991451517 hasConcept C2778580637 @default.
• W1991451517 hasConcept C2780009117 @default.
• W1991451517 hasConcept C2780868878 @default.
• W1991451517 hasConcept C71924100 @default.
• W1991451517 hasConcept C72563966 @default.
• W1991451517 hasConceptScore W1991451517C121608353 @default.
• W1991451517 hasConceptScore W1991451517C126322002 @default.
• W1991451517 hasConceptScore W1991451517C159654299 @default.
• W1991451517 hasConceptScore W1991451517C203014093 @default.
• W1991451517 hasConceptScore W1991451517C2777288759 @default.
• W1991451517 hasConceptScore W1991451517C2777451964 @default.
• W1991451517 hasConceptScore W1991451517C2777704310 @default.
• W1991451517 hasConceptScore W1991451517C2778220009 @default.
• W1991451517 hasConceptScore W1991451517C2778580637 @default.
• W1991451517 hasConceptScore W1991451517C2780009117 @default.
• W1991451517 hasConceptScore W1991451517C2780868878 @default.
• W1991451517 hasConceptScore W1991451517C71924100 @default.
• W1991451517 hasConceptScore W1991451517C72563966 @default.
• W1991451517 hasIssue "3" @default.
• W1991451517 hasLocation W19914515171 @default.
• W1991451517 hasLocation W19914515172 @default.
• W1991451517 hasOpenAccess W1991451517 @default.
• W1991451517 hasPrimaryLocation W19914515171 @default.
• W1991451517 hasRelatedWork W1964238405 @default.
• W1991451517 hasRelatedWork W1991451517 @default.
• W1991451517 hasRelatedWork W2002513481 @default.
• W1991451517 hasRelatedWork W2024012065 @default.
• W1991451517 hasRelatedWork W2038684671 @default.
• W1991451517 hasRelatedWork W2038915476 @default.

• next